The World Health Organisation has accidentally leaked disappointing data from a trial of Gilead’s coronavirus hopeful remdesivir in China.
According to media reports, the prematurely published information suggest that the drug failed to improve symptoms in patients with severe COVID-19 or reduce viral load, while side effects were also reported.
In a statement Gilead said the study had been removed from the WHO’s site as study investigators “did not provide permission for the publication of the results”.
“Furthermore, we believe the post included inappropriate characterisations of the study,” the firm stressed.
“The study was terminated early due to low enrolment and, as a result, it was underpowered to enable statistically meaningful conclusions…